Acrotech Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ACROTECH, and what generic alternatives to ACROTECH drugs are available?
ACROTECH has six approved drugs.
There are twelve US patents protecting ACROTECH drugs.
There are one hundred and seventy-nine patent family members on ACROTECH drugs in thirty-four countries and six supplementary protection certificates in five countries.
Drugs and US Patents for Acrotech
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Acrotech Biopharma | BELEODAQ | belinostat | POWDER;INTRAVENOUS | 206256-001 | Jul 3, 2014 | RX | Yes | Yes | 6,888,027 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Acrotech Biopharma | FUSILEV | levoleucovorin calcium | POWDER;INTRAVENOUS | 020140-001 | Mar 7, 2008 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
Acrotech Biopharma | FUSILEV | levoleucovorin calcium | SOLUTION;INTRAVENOUS | 020140-002 | Apr 29, 2011 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Acrotech Biopharma | EVOMELA | melphalan hydrochloride | POWDER;INTRAVENOUS | 207155-001 | Mar 10, 2016 | RX | Yes | Yes | 10,040,872 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Acrotech Biopharma | EVOMELA | melphalan hydrochloride | POWDER;INTRAVENOUS | 207155-001 | Mar 10, 2016 | RX | Yes | Yes | 11,020,363 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Acrotech Biopharma | FUSILEV | levoleucovorin calcium | SOLUTION;INTRAVENOUS | 020140-003 | Apr 29, 2011 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Acrotech Biopharma | EVOMELA | melphalan hydrochloride | POWDER;INTRAVENOUS | 207155-001 | Mar 10, 2016 | RX | Yes | Yes | 10,864,183 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Acrotech
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Acrotech Biopharma | FUSILEV | levoleucovorin calcium | SOLUTION;INTRAVENOUS | 020140-002 | Apr 29, 2011 | 6,500,829 | ⤷ Sign Up |
Acrotech | MARQIBO KIT | vincristine sulfate | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 202497-001 | Aug 9, 2012 | 7,247,316 | ⤷ Sign Up |
Acrotech | MARQIBO KIT | vincristine sulfate | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 202497-001 | Aug 9, 2012 | 7,887,836 | ⤷ Sign Up |
Acrotech | MARQIBO KIT | vincristine sulfate | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 202497-001 | Aug 9, 2012 | 5,543,152 | ⤷ Sign Up |
Acrotech Biopharma | FUSILEV | levoleucovorin calcium | POWDER;INTRAVENOUS | 020140-001 | Mar 7, 2008 | 6,500,829 | ⤷ Sign Up |
Acrotech | MARQIBO KIT | vincristine sulfate | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 202497-001 | Aug 9, 2012 | 5,814,335 | ⤷ Sign Up |
Acrotech | MARQIBO KIT | vincristine sulfate | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 202497-001 | Aug 9, 2012 | 6,723,338 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ACROTECH drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Injection | 50 mg/vial | ➤ Subscribe | 2017-09-08 |
➤ Subscribe | Injection | 50 mg/vial | ➤ Subscribe | 2013-12-19 |
➤ Subscribe | Injection | 500 mg/vial | ➤ Subscribe | 2018-07-03 |
➤ Subscribe | Injection | 10 mg/mL, 17.5 mL vial and 25 mL vial | ➤ Subscribe | 2011-10-26 |
➤ Subscribe | Injection | 20 mg/mL and 40 mg/2 mL | ➤ Subscribe | 2013-09-24 |
International Patents for Acrotech Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Denmark | 1328510 | ⤷ Sign Up |
Japan | 6060289 | ⤷ Sign Up |
Israel | 224229 | ⤷ Sign Up |
Hong Kong | 1177901 | ⤷ Sign Up |
South Africa | 201502935 | ⤷ Sign Up |
United Kingdom | 0023986 | ⤷ Sign Up |
Australia | 2013226073 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Acrotech Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2701720 | CA 2022 00054 | Denmark | ⤷ Sign Up | PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818 |
2701720 | CR 2022 00054 | Denmark | ⤷ Sign Up | PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818 |
2701720 | 23C1000 | France | ⤷ Sign Up | PRODUCT NAME: MELPHALAN FLUFENAMIDE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, TELS QUE LE CHLORHYDRATE; REGISTRATION NO/DATE: EU/1/22/1669 20220818 |
2701720 | 301206 | Netherlands | ⤷ Sign Up | PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/22/1669 20220818 |
2701720 | 122023000007 | Germany | ⤷ Sign Up | PRODUCT NAME: MELPHALANFLUFENAMID HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1669 20220817 |
2701720 | 3/2023 | Austria | ⤷ Sign Up | PRODUCT NAME: MELPHALANFLUFENAMID-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1669 (MITTEILUNG) 20220818 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.